5-vinyl-2,4-dichloropyrimidine | 137500-15-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-vinyl-2,4-dichloropyrimidine
• 英文别名: 2,4-Dichloro-5-vinylpyrimidine；2,4-dichloro-5-ethenylpyrimidine
• CAS: 137500-15-3
• 化学式: C₆H₄Cl₂N₂
• 分子量: 175.017
• InChiKey: GZHCIFXRWFBZCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-vinyl-2,4-dichloropyrimidine 在 potassium iodate 、 硫酸 、 碘 作用下， 以 水 、 乙腈 为溶剂， 反应 6.0h， 以68%的产率得到5-(1-hydroxy-2-iodoethyl)-2,4-dichloropyrimidine
  参考文献：
  名称：

  Synthesis and cytotoxic activity of 5-(1-hydroxy-2-haloethyl)-, 5-oxiranyl- and (E)-5-(2-iodovinyl)-2,4-dichloro (or dimethoxy) pyrimidines

  摘要：

  A series of 5-(1-hydroxy-2-haloethyl) 6, 7, 13, 14a, 5-oxiranyl 8, 9 and (E)-5-(2-iodovinyl)-2,4-dichloro(or dimethoxy)pyrimidines 11, 12 were synthesized for evaluation as cytotoxic agents. The nuclear C-2 and C-4 substituents were determinants of activity since the 2,4-dichloro compounds 6, 8 and 11 were more potent (ED50 = 0.2-0.3-mu-g/ml) than the corresponding 2,4-dimethoxypyrimidine analogues 7, 9 and 12 (ED50 = 4-28-mu-g/ml), relative to melphalan (ED50 = 0.15-mu-g/ml), in the in vitro L1210 screen. Within the 2,4-dichloro series of compounds 6, 8 and 11, the C-5 substituent was not a determinant of activity. In contrast, in the 2,4-dimethoxypyrimidine series, the C-5 substituents influenced activity significantly where the relative potency order was oxiranyl 9 > -CH(OH)CH2I 7 > (E)-CH = CHI 12 > CH(OH)CHI2 13, CH(OH)CHBr(I) 14a and CH(Br)CHOH(I) 14b. The most active compound (E)-5-(2-iodovinyl)-2,4-dichloropyrimidine 11 exhibited weak activity in the in vivo P388 screen (% T/C = 116 for a 10 mg/kg ip dose) relative to the reference drug 5-fluorouracil (% T/C = 135 for a 20 mg/kg dose).

  DOI：

  10.1016/0223-5234(91)90153-e
• 作为产物：
  描述：

  5-乙烯尿嘧啶 在 N,N-二乙基苯胺 、 三氯氧磷 作用下， 反应 0.5h， 以63.2%的产率得到5-vinyl-2,4-dichloropyrimidine
  参考文献：
  名称：

  Synthesis and cytotoxic activity of 5-(1-hydroxy-2-haloethyl)-, 5-oxiranyl- and (E)-5-(2-iodovinyl)-2,4-dichloro (or dimethoxy) pyrimidines

  摘要：

  A series of 5-(1-hydroxy-2-haloethyl) 6, 7, 13, 14a, 5-oxiranyl 8, 9 and (E)-5-(2-iodovinyl)-2,4-dichloro(or dimethoxy)pyrimidines 11, 12 were synthesized for evaluation as cytotoxic agents. The nuclear C-2 and C-4 substituents were determinants of activity since the 2,4-dichloro compounds 6, 8 and 11 were more potent (ED50 = 0.2-0.3-mu-g/ml) than the corresponding 2,4-dimethoxypyrimidine analogues 7, 9 and 12 (ED50 = 4-28-mu-g/ml), relative to melphalan (ED50 = 0.15-mu-g/ml), in the in vitro L1210 screen. Within the 2,4-dichloro series of compounds 6, 8 and 11, the C-5 substituent was not a determinant of activity. In contrast, in the 2,4-dimethoxypyrimidine series, the C-5 substituents influenced activity significantly where the relative potency order was oxiranyl 9 > -CH(OH)CH2I 7 > (E)-CH = CHI 12 > CH(OH)CHI2 13, CH(OH)CHBr(I) 14a and CH(Br)CHOH(I) 14b. The most active compound (E)-5-(2-iodovinyl)-2,4-dichloropyrimidine 11 exhibited weak activity in the in vivo P388 screen (% T/C = 116 for a 10 mg/kg ip dose) relative to the reference drug 5-fluorouracil (% T/C = 135 for a 20 mg/kg dose).

  DOI：

  10.1016/0223-5234(91)90153-e

文献信息

• Superacid-Promoted Additions Involving Vinyl-Substituted Pyrimidines, Quinoxalines, and Quinazolines: Mechanisms Correlated to Charge Distributions
  作者：Yiliang Zhang、Matthew R. Sheets、Erum K. Raja、Kenneth N. Boblak、Douglas A. Klumpp

  DOI：10.1021/ja202557z

  日期：2011.6.8

  quinoxalines, and quinazolines exhibit an unusual regioelectronic effect that controls the type of addition reaction observed. Depending on the ring position of the vinyl substituent, either conjugate addition or Markovnikov addition occurs. The mode of addition has been shown to correlate well to NBO calculated charges.

  已经研究了乙烯基取代的 N-杂环的超酸促进反应。双质子化嘧啶、喹喔啉和喹唑啉表现出不寻常的区域电子效应，可控制所观察到的加成反应类型。根据乙烯基取代基的环位置，发生共轭加成或马尔可夫尼科夫加成。添加方式已被证明与 NBO 计算的费用相关。
• GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS
  申请人：AXOVANT SCIENCES GMBH

  公开号：US20170369486A1

  公开（公告）日：2017-12-28

  The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.
• Synthesis and cytotoxic activity of 5-(1-hydroxy-2-haloethyl)-, 5-oxiranyl- and (E)-5-(2-iodovinyl)-2,4-dichloro (or dimethoxy) pyrimidines
  作者：R Kumar、EE Knaus、LI Wiebe、TM Allen、ML Tempest

  DOI：10.1016/0223-5234(91)90153-e

  日期：1991.7

  A series of 5-(1-hydroxy-2-haloethyl) 6, 7, 13, 14a, 5-oxiranyl 8, 9 and (E)-5-(2-iodovinyl)-2,4-dichloro(or dimethoxy)pyrimidines 11, 12 were synthesized for evaluation as cytotoxic agents. The nuclear C-2 and C-4 substituents were determinants of activity since the 2,4-dichloro compounds 6, 8 and 11 were more potent (ED50 = 0.2-0.3-mu-g/ml) than the corresponding 2,4-dimethoxypyrimidine analogues 7, 9 and 12 (ED50 = 4-28-mu-g/ml), relative to melphalan (ED50 = 0.15-mu-g/ml), in the in vitro L1210 screen. Within the 2,4-dichloro series of compounds 6, 8 and 11, the C-5 substituent was not a determinant of activity. In contrast, in the 2,4-dimethoxypyrimidine series, the C-5 substituents influenced activity significantly where the relative potency order was oxiranyl 9 > -CH(OH)CH2I 7 > (E)-CH = CHI 12 > CH(OH)CHI2 13, CH(OH)CHBr(I) 14a and CH(Br)CHOH(I) 14b. The most active compound (E)-5-(2-iodovinyl)-2,4-dichloropyrimidine 11 exhibited weak activity in the in vivo P388 screen (% T/C = 116 for a 10 mg/kg ip dose) relative to the reference drug 5-fluorouracil (% T/C = 135 for a 20 mg/kg dose).